Released Nov 9, 2026, after the close
10-Q filed Nov 9, 2026, 40 days after period end · 0001104659-26-124513
FURVENT did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR).
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $5.00M | — | — | — |
| Net Income | -$40.31M | -$34.98M | -$20.56M | -$14.40M |
ArriVent BioPharma, Inc. · CIK 1868279 · Engraved from SEC EDGAR
| EPS Diluted | -$0.81 | -$0.83 | -$0.61 | -$5.52 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
The Phase 3 FURVENT study did not meet its primary endpoint of progression-free survival; at 240 mg median PFS was 11.0 months versus 9.5 months with chemotherapy (HR 0.75; p=0.0654).¶1¶2
ArriVent reported a net loss of $133.5 million for the nine months ended September 30, 2026, and cash and investments of $393.2 million as of September 30, 2026.¶3¶4
Stuart Lutzker, M.D., Ph.D. notified ArriVent of his retirement as President, Research and Development and as a director, effective December 1, 2026, with a one-time payment of $428,438.21 under a planned retirement agreement.¶5¶6¶7
Priti Patel, M.D., the Chief Medical Officer, will assume leadership of research and development effective December 1, 2026, and Phase 1 ARR-217 data showed a 44.8% objective response rate in colorectal cancer at 6 mg/kg.¶8¶9